One dose of COVID-19 nanoparticle vaccine REVC-128 protects against SARS-CoV-2 challenge at two weeks post-immunization

• Published in: Emerging microbes & infections Vol. 10; no. 1; pp. 2016 - 2029
• Main Authors: Gu, Maggie, Torres, Jonathan L., Li, Yijia, Van Ry, Alex, Greenhouse, Jack, Wallace, Shannon, Chiang, Chi-I, Pessaint, Laurent, Jackson, Abigail M., Porto, Maciel, Kar, Swagata, Li, Yuxing, Ward, Andrew B., Wang, Yimeng
• Format: Journal Article
• Language: English
• Published: United States Taylor & Francis 01.01.2021; Taylor & Francis Ltd; Taylor & Francis Group
• Subjects: Animals; Antibodies, Neutralizing; Antibodies, Viral - blood; Antibody Formation; antibody-dependent enhancement (ADE); COVID-19 - prevention & control; COVID-19 vaccine; COVID-19 vaccines; COVID-19 Vaccines - administration & dosage; COVID-19 Vaccines - immunology; Cricetinae; Humans; Immunization; Immunization Schedule; Immunogenicity, Vaccine; Mesocricetus; Mice; nanoparticle vaccine; Nanoparticles; Nanoparticles - chemistry; one-dose regimen; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Spike Glycoprotein, Coronavirus; Vaccination; vaccine safety; vaccine stability; variants; Viral Load; vaccine safety; SARS-CoV-2; nanoparticle vaccine; one-dose regimen; COVID-19 vaccine; antibody-dependent enhancement (ADE); variants; vaccine stability

A COVID-19 vaccine that can give early protection is needed to eliminate the viral spread efficiently. Here, we demonstrate the development of a nanoparticle vaccine candidate, REVC-128, in which multiple trimeric spike ectodomains with glycine (G) at position 614 were multimerized onto a nanopartic...